RTN-001
Uncontrolled Hypertension
Phase 2Active
Key Facts
About Retension Pharmaceuticals
Retension Pharmaceuticals is a private, clinical-stage biotech targeting the large unmet need in uncontrolled hypertension with its lead candidate, RTN-001. This first-in-class, tissue-targeted PDE5 inhibitor is designed to act preferentially in the central pulmonary vasculature and is currently in Phase 2 trials. The company leverages a seasoned leadership team with deep experience in cardiovascular drug development to advance its pipeline.
View full company profileTherapeutic Areas
Other Uncontrolled Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Symplicity™ Spyral RDN System | Medtronic | PMA Under Review |